Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167332 | 0.83 | — | — | |
| SCHEMBL28241299 | 0.83 | — | — | |
| SCHEMBL2577858 | 0.83 | — | — | |
| SCHEMBL27806528 | 0.78 | HDAC1 (0.31) | — | |
| SCHEMBL1071254 | 0.78 | TAAR1 (0.30) | — | |
| SCHEMBL95729 | 0.78 | — | — | |
| SCHEMBL353016 | 0.78 | — | — | |
| SCHEMBL28216850 | 0.78 | AOC3 (0.35) | AOC3SLC6A4 | |
| SCHEMBL27729555 | 0.76 | HDAC4 (0.32) | KDM4EALDH1A1CYP3A4ALOX15ALOX12 | |
| SCHEMBL6633769 | 0.75 | DPP4 (0.36) | KDM4ELMNAADRA2CHIF1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | claimed |
| EP-1663960-B1 | AMIDINES AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2011-08-24 | — | — | EP | claimed |
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2043993-B1 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN INC (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2069295-B1 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2291353-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS USED AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8338637-B2 | Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid | ALLERGAN, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8252788-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2114875-B1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2008008700-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008701-A2 | SUBSTITUTED CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008008660-A2 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008718-A2 | CYCLOPENTANE DERIVATIVES AS ANTIGLAUCOMA AGENTS | ALLERGAN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007149829-A2 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER2 | KDM4E 2886/4885LMNA 3367/4885ADRA2C 56/4885 |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | THPO, HLA-C, PIGO | KDM4E 4700/4885LMNA 3173/4885ADRA2C 1366/4885 |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | PTGER2, PTGER1, PTGS2 | KDM4E 3080/4885LMNA 2290/4885ADRA2C 162/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | KDM4E 4067/4885LMNA 2115/4885ADRA2C 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.